Related Experiment Videos
[Clinical trial of cefmenoxime in children]
Insights
Cefmenoxime effectively treated bacterial infections in children, showing a 90% efficacy rate with minimal side effects. This antibiotic demonstrated significant therapeutic benefits in pediatric patients with serious conditions like pneumonia and meningitis.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Bacteriology
Background:
- Bacterial infections pose significant health risks in children.
- Intravenous antibiotics are crucial for treating severe pediatric bacterial infections.
- Cefmenoxime is a third-generation cephalosporin with broad-spectrum activity.
Observation:
- Cefmenoxime was administered intravenously to 20 children with various bacterial infections, including pneumonia, meningitis, pyothorax, urinary tract infections, and brain abscess.
- Dosages varied based on infection severity, ranging from 43-88 mg/kg/day for less severe infections to 145-311 mg/kg/day for meningitis, pyothorax, and brain abscess.
- The study identified causative organisms such as H. influenzae, S. aureus, Streptococcus sanguis, and E. coli.
Findings:
- Cefmenoxime demonstrated a high therapeutic efficacy rate of 90% (15 excellent, 3 good).
- The antibiotic successfully eliminated most causative organisms, with the exception of two strains of S. aureus.
- Transient eosinophilia was the only observed side effect in one patient.
Implications:
- Cefmenoxime is a safe and effective treatment option for a range of bacterial infections in pediatric patients.
- Its high efficacy and favorable safety profile support its use in clinical practice for severe pediatric infections.
- Further research could explore Cefmenoxime's role in combating antibiotic-resistant S. aureus strains.
Abstract:
Cefmenoxime (CMX) was intravenously administered to 20 children with the following bacterial infection; pneumonia in 14 cases, purulent meningitis in 2 cases, pyothorax in 2 cases, urinary tract infection in 1 case and brain abscess in 1 case. The daily dosage administered in meningitis, pyothorax and brain abscess ranged from 145-311 mg/kg/day, from 43-88 mg/kg/day in other bacterial infections. The therapeutic efficacy was excellent in 15, good in 3, poor in 2 patients, efficacy rate being 90%. Causative organisms were H. influenzae in 4 cases, S. aureus in 2 cases, Streptococcus sanguis in 1 case, E. coli in 1 case and unknown in 12 cases. All were eliminated with the exception of 2 strains of S. aureus after the administration of CMX. As for side effect, transient eosinophilia was only observed in 1 case.